Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.